<?xml version="1.0" encoding="UTF-8"?>
<!--REG30PARAB V1.0 (01-06-2026)-->
<xbrli:xbrl xmlns:in-capmkt="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt" xmlns:in-capmkt-ent="http://www.sebi.gov.in/xbrl/Regulation_30_Para_B_Of_Part_A_Of_Schedule_III/2026-04-30/in-capmkt/in-capmkt-ent" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:in-capmkt-types="http://www.sebi.gov.in/xbrl/2026-04-30/in-capmkt-types" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.w3.org/1999/xlink"><link:schemaRef xlink:type="simple" xlink:href="in-capmkt-ent-2026-04-30.xsd"/><xbrli:context id="MainI"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">544647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I_AtTheTimeOfBecomingPartyToLitigationOrAssessmentOrAdjudicationOrArbitrationOrDispute"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">544647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-09-01</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:explicitMember dimension="in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIIIAxis">in-capmkt:AtTheTimeOfBecomingPartyToLitigationOrAssessmentOrAdjudicationOrArbitrationOrDisputeMember</xbrldi:explicitMember></xbrli:scenario></xbrli:context><xbrli:context id="I_OppositePartyAsPerSubPara8OfParaB1"><xbrli:entity><xbrli:identifier scheme="http://www.sebi.gov.in/in-capmkt/ScripCode">544647</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-09-01</xbrli:instant></xbrli:period><xbrli:scenario><xbrldi:typedMember dimension="in-capmkt:OppositePartyAsPerSubPara8OfParaBAxis"><in-capmkt:OppositePartyAsPerSubPara8OfParaBDomain>OppositePartyAsPerSubPara8OfParaBDomain1</in-capmkt:OppositePartyAsPerSubPara8OfParaBDomain></xbrldi:typedMember></xbrli:scenario></xbrli:context><in-capmkt:NSESymbol contextRef="MainI">NEPHROPLUS</in-capmkt:NSESymbol><in-capmkt:NameOfTheCompany contextRef="MainI">Nephrocare Health Services Limited</in-capmkt:NameOfTheCompany><in-capmkt:ScripCode contextRef="MainI">544647</in-capmkt:ScripCode><in-capmkt:MSEISymbol contextRef="MainI">NA</in-capmkt:MSEISymbol><in-capmkt:ISIN contextRef="MainI">INE428V01029</in-capmkt:ISIN><in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">Pendency of any litigation(s) or dispute(s) (Sub-para 8-Para B)</in-capmkt:TypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="I_AtTheTimeOfBecomingPartyToLitigationOrAssessmentOrAdjudicationOrArbitrationOrDispute">At the time of becoming the party to any litigation, assessment, adjudication, arbitration or dispute</in-capmkt:SubTypeOfEventAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII contextRef="MainI">New</in-capmkt:TypeOfAnnouncementAsPerRegulation30ParaBOfPartAOfScheduleIII><in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting contextRef="MainI">false</in-capmkt:WhetherEventOrInformationDisclosedIsAnOutcomeOfTheBoardMeeting><in-capmkt:DateOfOccurrenceOfEventOrInformation contextRef="MainI">2026-08-24</in-capmkt:DateOfOccurrenceOfEventOrInformation><in-capmkt:TimeOfOccurrenceOfEventOrInformation contextRef="MainI">13:00:00</in-capmkt:TimeOfOccurrenceOfEventOrInformation><in-capmkt:DateOfReport contextRef="MainI">2026-09-01</in-capmkt:DateOfReport><in-capmkt:NameOfOppositeParties contextRef="I_OppositePartyAsPerSubPara8OfParaB1">Tashkent City Tax Department, Uzbekistan (“Tax Department”)</in-capmkt:NameOfOppositeParties><in-capmkt:DateOfInitiationOfLitigation contextRef="I_OppositePartyAsPerSubPara8OfParaB1">2026-08-24</in-capmkt:DateOfInitiationOfLitigation><in-capmkt:NameOfAuthorityWhereLitigationIsFiled contextRef="I_OppositePartyAsPerSubPara8OfParaB1">Agency</in-capmkt:NameOfAuthorityWhereLitigationIsFiled><in-capmkt:DetailsOfAuthorityWhereLitigationIsFiled contextRef="I_OppositePartyAsPerSubPara8OfParaB1">Tashkent City Tax Department, Uzbekistan (“Tax Department”)</in-capmkt:DetailsOfAuthorityWhereLitigationIsFiled><in-capmkt:PartyToTheLitigation contextRef="I_OppositePartyAsPerSubPara8OfParaB1">Subsidiary</in-capmkt:PartyToTheLitigation><in-capmkt:DetailsOfPartyToTheLitigation contextRef="I_OppositePartyAsPerSubPara8OfParaB1">Pursuant to the review of the tax audit results, the
Tashkent City Tax Department has determined
additional taxes of UZS 20,371,068,018
(approximately ₹16.50 crore), against which
reductions of UZS 6,167,012,658 (approximately ₹4.99
crore) have been allowed, resulting in a net additional
tax assessment of UZS 14,204,055,360 (approximately
₹11.50 crore). Further, a financial penalty of UZS
4,064,086,532 (approximately ₹3.29 crore) has been
imposed under Article 224 of the applicable tax law.
Accordingly, the net additional tax assessment and
financial penalty aggregate to UZS 18,268,141,892
(approximately ₹14.79 crore), excluding applicable
late-payment interest under Article 110.</in-capmkt:DetailsOfPartyToTheLitigation><in-capmkt:BriefDetailsOfLitigationOrDispute contextRef="I_OppositePartyAsPerSubPara8OfParaB1">Nephrocare Health Services Central Asia LLC (“NCA”), an overseas wholly-owned subsidiary of
Nephrocare Health Services Limited (“Company”), has received an Order on the Review of Tax
Audit Results No. 721.1 dated August 24, 2026 (“Order”) from the Tashkent City Tax
Department, Uzbekistan (“Tax Department”), pursuant to a tax audit conducted for the period
from January 1, 2023 to December 31, 2025.</in-capmkt:BriefDetailsOfLitigationOrDispute><in-capmkt:ExpectedFinancialImplicationsOfLitigation contextRef="I_OppositePartyAsPerSubPara8OfParaB1">Based on the preliminary assessment and subject to
the outcome of the reconciliation and/or legal
remedies that may be pursued, the Company is of the
opinion that the aforesaid order should be setaside/
quashed and hence, the same does not have a
material adverse impact on the financial position,
operations or business of the Company.
However, in line with the assessment order the
aggregate exposure is approximately ₹14.79 crore,
comprising net additional tax assessment of
approximately ₹11.50 crore and penalty of
approximately ₹3.29 crore, excluding applicable latepayment
interest.</in-capmkt:ExpectedFinancialImplicationsOfLitigation><in-capmkt:QuantumOfClaimsInLitigation contextRef="I_OppositePartyAsPerSubPara8OfParaB1">The Company has undertaken a preliminary assessment of the order and is evaluating the available legal remedies under the applicable laws, including the right to appeal the order. The order provides that the amounts assessed thereunder become effective one month after the order is presented to the taxpayer.
The Company is presently evaluating the Decision and the legal remedies available under applicable laws. No appeal or legal proceedings have been initiated as on the date of this disclosure.
Not applicable. The matter relates to a tax assessment and financial penalty imposed by the tax authority and does not involve any claim made by the Company.</in-capmkt:QuantumOfClaimsInLitigation></xbrli:xbrl>
